DARA BioSciences, recently awarded fast track designation from the FDA for the development of their new drug for the treatment of neuropathic pain, has just released the results of a Phase II safety and efficacy study. The study showed KRN5500 demonstrated a statistically significant improvement in the relief of neuropathic pain versus a placebo. READ MORE
Source: Newswise